Infection and Vaccines
Addressing infectious diseases
Jump to section:
AstraZeneca is committed to developing and implementing scientific advancement in infection and vaccines.
We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics.
In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide. RSV disease is the leading cause of hospitalisation in children under one year of age in the United States
Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.
Our focus on infectious diseases
Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.
-
Antimicrobial resistance (AMR)
AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.
-
Seasonal influenza
Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.
25,000
In Europe alone, AMR causes 25,000 deaths every year; two thirds of these are due to Gram-negative bacteria.
1.5 billion
AMR will result in 1.5 billion EUR extra healthcare costs and productivity losses across Europe, based on 2007 estimates.
1 billion
There are an estimated 1 billion cases of influenza each year worldwide.
300,000-500,000
Each year there are around 300,000-500,000 deaths due to influenza worldwide.
Our medicines
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Synagis
palivizumab
Fluenz Tetra/FluMist Quadrivalent
influenza vaccine live, intra-nasal
Resources
Sharing clinical trials information
We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.
Information about our medicines
Our medicines are approved in individual countries for specific uses. Visit your local AstraZeneca site to find out more
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Veeva ID: Z4-17493
Date of next review: 07/06/2021